Prospects for paratransgenic applications to commercial mariculture using genetically engineered algae.
R. V. Durvasula , S. K. Matthews , P. Sundaram , R. K. Sundaram
Science Publishers, Inc. 865 -889
3
2006
Expression of a functional single-chain antibody via Corynebacterium pseudodiphtheriticum.
R. K. Sundaram , I. Hurwitz , S. Matthews , E. Hoy
European Journal of Clinical Microbiology & Infectious Diseases 27 ( 7) 617 -622
12
2008
Prosthetic Rehabilitation of Composite Hemi-Facial Defects – A Case Report
R Kumara Sundaram , SK Bhandari , Poonam Prakash
International Journal of Contemporary Medical Research [IJCMR] 6 ( 4)
2019
All Ceramic Materials in Dentistry: Past, Present and Future: A Review
R Kumara Sundaram , Bensy Varghese
International Journal of Contemporary Medical Research [IJCMR] 7 ( 2)
2020
Chronic intestinal inflammation inhibits Na-glucose co-transport in rabbit ileal villus cells
A. B. West , V. M. Rajendran , U. Sundaram , R. K. Sundaram
Gastroenterology 106(4 Suppl. ) 274
1994
Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors.
Ranjit S Bindra , Ranjini K Sundaram , Juan C Vasquez , Sachita Ganesa
NAR cancer 3 ( 2)
2021
Unlocking PARP inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform.
Ranjit Bindra , Ranjini K Sundaram , Robert J Aiello , Dan Marshall
Journal of Clinical Oncology 37
1
2019
Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma
Sachita Ganesa , Amrita Sule , Ranjini K Sundaram , Ranjit S Bindra
Scientific Reports 12 ( 1) 5827
4
2022
Mechanism-based design of agents that selectively target drug-resistant glioma
Kingson Lin , Susan E Gueble , Ranjini K Sundaram , Eric D Huseman
Science 377 ( 6605) 502 -511
5
2022
Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers
Eric D Huseman , Anna Lo , Olga Fedorova , James L Elia
Journal of the American Chemical Society
2024
Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity
Sophia Gayle , Robert Aiello , Nalin Leelatian , Jason M Beckta
NAR cancer 3 ( 2) zcab021 -zcab021
18
2021
Correction to ‘Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity’
Sophia Gayle , Robert Aiello , Nalin Leelatian , Jason M Beckta
NAR cancer 3 ( 4) zcab047 -zcab047
1
2021
for Enhanced and Sustained Drug Delivery to Treat Brain Tumors
Evan M Chen , Amanda R Quijano , Young-Eun Seo , Christopher Jackson
2018
Development and validation of a novel IDH1-mutant astrocyte cell line as a model for high-grade gliomas
Nathaniel D Robinson , Karin R Purshouse , Nathan R Fons , Gregory A Breuer
Cancer Research 76 ( 14_Supplement) 4277 -4277
2016
Exploiting Metabolic Defects in Glioma with Nanoparticle-Encapsulated NAMPT Inhibitors
Matthew A Murray , Katelyn J Noronha , Yazhe Wang , Anna P Friedman
Molecular Cancer Therapeutics OF1 -OF12
2
2024
Convection enhanced delivery of a novel ATR inhibitor synergizes with systemic lomustine for improved treatment of glioblastoma
Alexander Josowitz , Teresa Lee , Ranjini K Sundaram , Jinal Pothupitiya
Cancer Research 84 ( 6_Supplement) 7117 -7117
2024
Exploiting mutant PPM1D-induced metabolic defects with nanoparticle-encapsulated NAMPT inhibitors
Matthew Murray , Yazhe Wang , Ranjini K Sundaram , Jason Beckta
Cancer Research 82 ( 12_Supplement) 294 -294
2022
Local DNA Repair Inhibition for Sustained Radiosensitization of High-Grade Gliomas.
Amanda R King , Christopher D Corso , Evan M Chen , Eric Song
Molecular Cancer Therapeutics 16 ( 8) 1456 -1469
16
2017
Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity
Jennifer Garbarino , Jillian Eckroate , Ranjini K Sundaram , Ryan B Jensen
Translational Oncology 14 ( 9) 101147 -101147
32
2021
TOP1-DNA trapping by exatecan and combination therapy with ATR inhibitor
Ukhyun Jo , Yasuhisa Murai , Keli K Agama , Yilun Sun
Molecular Cancer Therapeutics 21 ( 7) 1090 -1102
7
2022